Healthcare
Knight Therapeutics Inc.(KHTRF)
Live Price
Offline$6.70
+0.00% today
1Y Change
+50.90%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $740.00M
- Revenue Growth
- +21.1%
- EPS Growth
- -220.9%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Knight Therapeutics Inc. (KHTRF) is a Healthcare stock with a market cap of $740.00M and listed on OTC. The stock last traded around $6.70 and up 50.9% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +21.1%, EPS growth of -220.9%, a dividend yield of 0.0%. What stands out right now is revenue +21.1%, EPS -220.9%, free cash flow +1321.4% with operating margin -0.5% and ROIC -0.2%. Valuation is more restrained than many high-expectation growth names at price/sales 1.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines KHTRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+21.1% vs +7.6% peer median
Operating Margin
Below sector median
-0.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +21.1% and EPS is at -220.9%, with operating margin around -0.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.1% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +3.4% | +0.2% | +0.0% |
2026 Mar 19, 2026 | +2352.2% | +3.2% | +15.6% | +21.9% |
2025 Nov 6, 2025 | -458.8% | +1.0% | +2.6% | +1.4% |
Benchmark Edge
KHTRF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KHTRF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KHTRF Max Drawdown
-13.71%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KHTRF and SPY.
Company Overview
Knight Therapeutics Inc.
Other OTC
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.
- Leadership
- Samira Sakhia
- IPO Date
- Apr 3, 2014
- Employees
- 745
- Street Address
- 3400 De Maisonneuve Boulevard West
- Mailing
- Montreal, QC, H3Z 3B8
- Region
- Montreal, QC, CA
- Reporting Currency
- USD
- Investor Line
- 514-484-4483
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 14.4
- Price/Sales
- 1.6
- Price/Book
- 1.0
Growth
- Revenue
- +21.1%
- EPS
- -220.9%
- Free Cash Flow
- +1321.4%
Profitability
- Gross Margin
- 38.0%
- Operating Margin
- -0.5%
- Net Margin
- -1.2%
- ROE
- -0.7%
- ROIC
- -0.2%
Balance Sheet
- Debt/Equity
- 0.10
- Current Ratio
- 2.39
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.